TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00101400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg administered twice daily (b.i.d.)
Study: NCT00064662

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Burch Modified Tanagho
Description: The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous Fascia Sling
Description: The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
Study: NCT03891069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHA Exergame System
Description: The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
Study: NCT02237807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET
Study: NCT01485679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
Description: 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
Study: NCT02492750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study: NCT03747263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
Study: NCT00310713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
Study: NCT00305760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
Study: NCT02492750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given SC
Study: NCT03747263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
Study: NCT02553720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise in water
Description: The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
Study: NCT00305760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic tumor vaccine
Description: Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
Study: NCT00649662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Extended-Release Tablets 1000 mg
Description: 1000mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro® XR Tablets 1000 mg
Description: 1000mg, single dose fasting
Study: NCT01217047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
Study: NCT04089462

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Five sessions per period - Two sessions per period
Description: Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Two sessions per period - Five sessions per period
Description: Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)
Study: NCT00403806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: intravenous dexamethasone 0.05 mg per kg bodyweight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone 0.15 mg per kg bodyweight
Study: NCT02553720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic activity plus conventional management
Description: walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
Study: NCT01217047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
Study: NCT00403806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Intravenous dexamethasone 0.5 mg per kg bodyweight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline
Study: NCT02553720

Intervention type: OTHER
Group type: OTHER
Intervention: aquatic activity plus conventional management
Description: walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
Study: NCT04534426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Arnica montana
Description: In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
Study: NCT01217047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling without FES
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
Study: NCT04534426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucopolysaccharide polysulfate
Description: In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: In Control group, only standard therapy was performed after surgery
Study: NCT02154854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted half-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted plain dose
Study: NCT01217047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
Study: NCT02490930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
Study: NCT03302910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Stay Unit
Description: Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
Study: NCT03250312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Osteopathic Manipulation
Description: The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
Study: NCT00799461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: internet-based intervention
Description: Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completion of questions in an online format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completion of questions in an online format

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: questionnaire administration
Description: Completion of questions in an online format
Study: NCT04691596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-cue-contingent weekly incentives
Description: Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-cue-contingent weekly incentives
Description: Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-contingent weekly incentives
Description: Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Coaching
Description: Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Coaching
Description: Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
Study: NCT00799461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Assessment and care of psychosocial aspects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Assessment and care of psychosocial aspects

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: psychosocial assessment and care
Description: Assessment and care of psychosocial aspects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Evaluation of complications of treatment
Study: NCT01217047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
Study: NCT02144246

Intervention type: OTHER
Group type: OTHER
Intervention: Non-hormonal period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
Study: NCT02155855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine care
Study: NCT00799461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Evaluation of complications of treatment

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: assessment of therapy complications
Description: Evaluation of complications of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Managing therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Managing therapy complications

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: management of therapy complications
Description: Managing therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Description: Assessing and managing fatigue
Study: NCT01257893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid)
Description: Aspirin one 81 mg capsule per day for 10-14 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
Study: NCT03379493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1 ARTEMIS™ T cells
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
Study: NCT02365064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirCurve 10 ASV
Description: Device is able to provide both ASV therapy and CPAP therapy modes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirCurve 10 ASV
Description: Device is able to provide both ASV therapy and CPAP therapy modes.
Study: NCT03575364

Intervention type: DEVICE
Intervention: ClotTriever
Description: Thrombectomy

Intervention type: DEVICE
Intervention: ClotTriever
Description: Thrombectomy